Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 2, 2012, Pages 141-153

  Korolenko, Tatyana A ^a   Tuzikov, Fedor V ^b,c   Cherkanova, Marina S ^a   Johnston, Thomas P ^d   Tuzikova, Natalia A ^b,c   Loginova, Viktoriya M ^a   Filjushina, Elena E ^a   Kaledin, Vassilij I ^e  

^a INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^b BORESKOV INSTITUTE OF CATALYSIS   (Russian Federation)

^c NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

Author keywords

Atorvastatin; Carboxymethylated glucan; Lipemia; Lipoprotein fractions and subfractions; Matrix metalloproteases

Indexed keywords

ATORVASTATIN; BETA 1,3 GLUCAN; CARBOXYMETHYLATED BETA GLUCAN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; POLOXAMER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HYPERLIPIDEMIA; INSTITUTE FOR CANCER RESEARCH MOUSE; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

ANIMALS; BETA-GLUCANS; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIVER; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED ICR; POLOXAMER; PYRROLES; SCATTERING, SMALL ANGLE; TIME FACTORS; TRIGLYCERIDES; X-RAY DIFFRACTION;

EID: 84856868988     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y11-118     Document Type: Article

References (42)

1. Battilana, P., Ornstein, K., Minehira, K., Schwarz, J.M., Acheson, K., Schneiter, P., et al. 2001. Mechanisms of action of b-glucan in postprandial glucose metabolism in healthy men. Eur. J. Nutr. 55 (5): 327-333. doi:10.1038/sj.ejcn.1601160. PMID:11378805.
2. Burkhardt, R., Toh, S.A., Lagor, W.R., Birkeland, A., Levin, M., Li, X., et al. 2010. Trib1 is a lipid-and myocardial infarctionassociated gene that regulates hepatic lipogenesis and VLDL production in mice. J. Clin. Invest. 120(12): 4410-4414. doi:10.1172/JCI44213. PMID:21084752.
3. Butler, G.S., Dean, R.A., Morrison, C.J., and Overall, C.M. 2010. Identification of cellular MMP substrates using quantitative proteomics isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ). Methods Mol. Biol. 622: 451-470. doi:10.1007/978-1-60327-299-5_26. PMID:20135298.
4. Canadian Council on Animal Care. 1984. CCAC Guide to care and use of experimental animals. Vol.2. CCAC, Ottawa, Ont. Canadian Council on Animal Care. 1993. CCAC Guide to care and use of experimental animals. Vol.1. 2nd ed. CCAC, Ottawa, Ont.
5. Chow, A.K., Cena, J., and Schulz, R. 2007. Acute actions and novel targets of matrix metalloproteases in the heart and vasculature. Br. J. Pharmacol. 152(2): 189-205. doi:10.1038/sj.bjp.0707344. PMID:17592511.
6. Dergunova, M.A., Alexeenko, T.V., Zhanaeva, S.Y., Filyushina, E.E., Buzueva, I.I., Kolesnikova, O.P., et al. 2009. Characterization of the novel chemically modified fungal polysaccharides as the macrophage stimulators. Int. Immunopharmacol. 9(6): 729-733. doi:10.1016/j.intimp.2009.02.009. PMID:19268718.
7. Derosa, G., Maffioli, P., D'Angelo, A., Salvadeo, S.A., Ferrari, I., Fogari, E., et al. 2009. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin. Invest. Med. 32(2): E124-E132. PMID:19331801.
8. Eussen, S.R., Rompelberg, C.J., Andersson, K.E., Klungel, O.H., Hellstrand, P., Oste, R., et al. 2011. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDL r-/- mice. Pharmacol. Res. 64(1): 36-43. doi:10.1016/j.phrs.2011.02.008. PMID:21371558.
9. Goodridge, H.S., Wolf, A.J., and Underhill, D.M. 2009. Beta-glucan recognition by the innate immune system. Immunol. Rev. 230(1): 38-50. doi:10.1111/j.1600-065X.2009.00793.x. PMID:19594628.
10. Gupta, A., Badyal, D.K., Khosla, P.P., Uppal, B., Jaison, T.M., and Chopra, S. 2008. Effect of atorvastatin on hs-CRP in acute coronary syndrome. Br. J. Clin. Pharmacol. 66(3): 411-413. doi:10.1111/j.1365-2125.2008.03172.x. PMID:18637893.
11. Harchaoui, K.E.L., Visser, M.E., Kastelein, J.J.P., Stroes, E.S., and Dallinga-Thie, G.M. 2009. Triglycerides and cardiovascular risk. Curr. Cardiol. Rev. 5(3): 216-222. doi:10.2174/157340309788970315. PMID:20676280.
12. Johnston, T.P., Emeson, E.E., and Palmer, W.K. 1998. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis, 139: 115-123. PMID:9544738.
13. Johnson, E., Forland, D.T., Saetre, L., Bernardshaw, S.V., Lyberg, T., and Hetland, G. 2009. Effect of an extract based on the medicinal mushroom Agaricus blazei murill on release of cytokines, chemokines and leukocyte growth factors in human blood ex vivo and in vivo. Scand. J. Immunol. 69(3): 242-250. doi:10.1111/j.1365-3083.2008.02218.x. PMID:19281536.
14. Johnston, T.P. 2004. The P-407-induced murine model of dosecontrolled hyperlipidemia and atherosclerosis: a review of findings to date. J. Cardiovasc. Pharmacol. 43(4): 595-606. doi:10.1097/00005344-200404000-00016. PMID:15085072.
15. Johnston, T.P., and Palmer, W.K. 1997. The effect of pravastatin on hepatic 3-hydroxy-3-ethylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy, 17 (2): 342-347. PMID:9085326.
16. Johnston, T.P., Nguyen, L.B., Chu, W.A., and Shefer, S. 2001. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int. J. Pharm. 229(1/2): 75-86. doi:10.1016/S0378-5173(01)00834-1. PMID:11604260.
17. Kleemann, R., Verschuren, L., Morrison, M., Zadelaar, S., van Erk, M.J., Wielinga, P.Y., and Kooistra, T. 2011. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis, 218(1): 44-52. doi:10.1016/j.atherosclerosis.2011.04.023. PMID:21601209.
18. Knäuper, V., Will, H., López-Otin, C., Smith, B., Atkinson, S.J., Stanton, H., et al. 1996. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J. Biol. Chem. 271(29): 17124-17131. PMID:8663255.
19. Knight, C.G., Willenbrock, F., and Murphy, G. 1992. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 296(3): 263-266. doi:10.1016/0014-5793(92)80300-6. PMID:1537400.
20. Kogan, G., Pajtinka, M., Babincova, M., Miadokova, E., Rauko, P., Slamenova, D., and Korolenko, T.A. 2008. Yeast cell wall polysaccharides as antioxidants and antimutagens: can they fight cancer? Neoplasma, 55(5): 387-393. PMID:18665748.
21. Korolenko, T.A., Tuzikov, F.V., Johnston, T.P., Tuzikova, N., Filjushina, E.E., Loginova, V.M., and Savchenko, N.G. 2010. Influence of poloxamer 407 on fractional and subfractional composition of serum lipoproteins of mice. Health, 2(7): 722-730. doi:10.4236/health.2010.27110.
22. Korolenko, T., Cherkanova, M., Tuzikov, F., Johnston, T., Tuzikova, N., Loginova, V., and Kaledin, V. 2011. Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipemia. J. Pharm. Pharmacol. 63(6): 833-839. doi:10.1111/j.2042-7158.2011.01287.x. PMID:21585382.
23. Liao, J.K., and Laufs, U. 2005. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45(1): 89-118. doi:10.1146/annurev.pharmtox.45.120403.095748. PMID:15822172.
24. Lombard, C., Saulnier, J., and Wallach, J. 2005. Assays of matrix metalloproteinases (MMPs) activities: a review. Biochimie, 87(3/4): 265-272. doi:10.1016/j.biochi.2005.01.007. PMID:15781313.
25. Luan, Z., Chase, A.J., and Newby, A.C. 2003. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol. 23(5): 769-775. doi:10.1161/01.ATV.0000068646.76823.AE. PMID:12663370.
26. Millar, J.S., Cromley, D.A., McCoy, M.G., Rader, D.J., and Billheimer, J.T. 2005. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J. Lipid Res. 46(9): 2023-2028. doi:10.1194/jlr.D500019-JLR200. PMID:15995182.
27. Nachtigal, P., Pospisilova, N., Jamborova, G., Pospechova, K., Solichova, D., Andys, C., et al. 2007. Endothelial expression of endoglin in normocholestrolemic and hypercholesterolemic C57 BL/6J mice before and after atorvastatin treatment. Can. J. Physiol. Pharmacol. 65(8): 763-773. PMID:17901886.
28. Nicholls, S.J., Tuzcu, E.M., Schoenhagen, P., Sipahi, I., Crowe, T., Kapadia, S., and Nissen, S.E. 2005. Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study). Am. J. Cardiol.96(12): 1636-1639. PMID:16360349.
29. Nicholls, S.J., Tuzcu, E.M., Sipahi, I., Grasso, A.W., Schoenhagen, P., Hu, T., et al. 2007. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA, 297(5): 499-508. doi:10.1001/jama.297.5.499. PMID:17284700.
30. Otvos, J.D. 2002. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin. Lab. 48(3/4): 171-180. PMID:11934219.
31. Qiu, G., and Hill, J.S. 2007. Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J. Lipid Res. 48(10): 2112-2122. doi:10.1194/jlr.M600510-JLR200. PMID:17644777.
32. Roglans, N., Verd, J.C., Peris, C., Alegret, M., Vázguez, M., Adzet, T., et al. 2002. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids, 37(5): 445-454. doi:10.1007/s11745-002-0916-0. PMID:12056585.
33. Rondanelli, M., Opizzi, A., and Monteferrario, F. 2009. Le attività biologiche dei beta-glucani. [The biological activity of betaglucans] Minerva Med. 100(3): 237-245. PMID:19571787.
34. Sukhova, G.K., Williams, J.K., and Libby, P. 2002. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler. Thromb. Vasc. Biol. 22 (9): 1452-1458. doi:10.1161/01.ATV.0000030360.72503.56. PMID:12231565.
35. Sundström, J., and Vasan, R.S. 2006. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr. Opin. Lipidol. 17(1): 45-53. doi:10.1097/01.mol.0000203891.34890.b5. PMID:16407715.
36. Tentolouris, N., Eleftheriadou, I., and Katsilambros, N. 2009. The effect of medications used for the management of dyslipidemia on postprandial lipemia. Curr. Med. Chem. 16(2): 203-217. doi:10.2174/092986709787002763. PMID:19149572.
37. Tuzikov, F.V., Tuzikova, N.A., Galimov, R.V., Panin, L.E., and Nevinsky, G.A. 2002. General model to describe the structure and dynamic balance between different human serum lipoproteins and its practical application. Med. Sci. Monit. 8(6): MT79-MT88. PMID:12070444.
38. Vetvicka, V., and Vetvickova, J. 2009. Effects of yeast-derived betaglucans on blood cholesterol and macrophage functionality. J. Immunotoxicol. 6(1): 30-35. doi:10.1080/15476910802604317. PMID:19519160.
39. Visser, M.E., Jakulj, L., Kastelein, J.J., and Stroes, E.S. 2008. LDLC- lowering therapy: current and future therapeutic targets. Curr. Cardiol. Rep. 10(6): 512-520. doi:10.1007/s11886-008-0080-7. PMID:18950563.
40. Vondrakova, D., Ostadal, P., and Kruger, A. 2010. Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome. Lipids Health Dis. 9(1): 71. doi:10.1186/1476-511X-9-71. PMID:20053284.
41. Warren, A., Benseler, V., Cogger, V.C., Bertolino, P., and Le Couteur, D.G. 2011. The impact of poloxamer 407 on the ultrastructure of the liver and evidence for clearance by extensive endothelial and Kupffer cell endocytosis. Toxicol. Pathol. 39(2): 390-397. doi:10.1177/0192623310394212. PMID:21257999.
42. Will, H., Atkinson, S.J., Butler, G.S., Smith, B., and Murphy, G. 1996. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves propeptide of progelatinase A and inhibites autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 271(29): 17119-17123. doi:10.1074/jbc.271.29.17119. PMID:8663332.